14 recruiting, 4 not yet recruiting, 1 active not recruiting, 1 approved for marketing. 5 Phase 2, 4 Phase 1, 2 Early Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 1 | 4 | Recruiting 2, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Cutaneous Squamous Cell Carcinoma (CSCC): new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma (CSCC) trials Research Report on Cutaneous Squamous Cell Carcinoma (CSCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| Flash Radiotherapy for Skin Cancer FLASH radiotherapy, Conventional radiotherapy - Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC) | Phase 2 | Recruiting | Jules Bordet Institute | 60 | 2026-08-24 | 2026-11-17 |
| D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab Pretreatment D-dimer status - Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 116 | 2026-08-01 | 2026-07-22 | |
| A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors KUP-101A - Cutaneous Melanoma, Mucosal Melanoma | Phase 1 | Recruiting | Kupando GmbH | 21 | 2026-07-03 | 2026-11-18 |
| A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients Topical niacinamide 5% cream, Sunscreen - Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC) | Early Phase 1 | Recruiting | Marissa Lobl | 20 | 2026-05-01 | 2026-06-05 |
| Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma Pucotenlimab, Becotatug Vedotin - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Fudan University | 38 | 2026-01-09 | 2026-02-06 |
| Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence High-Frequency Ultrasound, Dermoscopy - Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC) | Not yet recruiting | Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji | 400 | 2025-12-23 | 2026-01-23 | |
| A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma tolododekin alfa - Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant | Phase 1 | Withdrawn | Ankyra Therapeutics, Inc | 2025-12-15 | 2026-06-25 | |
| Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab. Cemiplimab - Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | Instituto de Investigación Biomédica de Salamanca | 30 | 2025-07-17 | 2026-11-09 | |
| MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer Short course radiation, Active Surveillance - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Recruiting | University of Vermont Medical Center | 24 | 2025-06-04 | 2026-05-26 |
| Towards Cure Via Only Ultra-short ICB in CSCC Nivolumab, Ipilumimab - Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 41 | 2025-05-14 | 2025-05-29 |
| Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence Adjuvant radiotherapy - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | Recruiting | Centre Leon Berard | 266 | 2025-02-21 | 2026-04-24 |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma Cemiplimab, Standard of care - Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 369 | 2025-01-02 | 2026-09-16 |
| Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers Blood draw for the laboratory assessment - Skin Cancer, Melanoma (Skin Cancer) | Active not recruiting | University of Wisconsin, Madison | 20 | 2024-12-11 | 2026-05-29 | |
| A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision Fluzone Trivalent - Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC) | Early Phase 1 | Recruiting | Dana-Farber Cancer Institute | 25 | 2024-11-26 | 2026-10-19 |
| Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Recruiting | University of California, San Francisco | 250 | 2024-10-09 | 2025-12-12 | |
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-11-17 |
| Usefulness of Post-Operative Radiotherapy in High-grade Cutaneous Squamous Cell Carcinoma: an Observational Study Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 120 | 2023-11-17 | 2025-03-17 | |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment. Systemic treatment - Cutaneous Squamous Cell Carcinoma (CSCC) | Recruiting | University Hospital, Lille | 1500 | 2021-07-09 | 2026-05-26 |
Showing 20 of 22. Sign in to see all of them.
Skin Neoplasms (7) · Carcinoma, Basal Cell (6) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Carcinoma, Renal Cell (1) · Histiocytoma, Malignant Fibrous (1) · Keratosis, Actinic (1) · Kidney Neoplasms (1) · Leiomyosarcoma (1) · Margins of Excision (1) · Mesothelioma (1) · Recurrence (1)
Neoplasms (12) · Neoplasms by Site (12) · Carcinoma (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Neoplasms, Basal Cell (6) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3)
cemiplimab (4) · Blood Specimen Collection (2) · Cetuximab (1) · Dermoscopy (1) · Erlotinib Hydrochloride (1) · Histocompatibility Testing (1) · Immunotherapy (1) · Influenza Vaccines (1) · Lymph Node Excision (1) · Neoadjuvant Therapy (1) · Niacinamide (1) · Nivolumab (1) · Prednisone (1) · Radiotherapy, Adjuvant (1) · Sirolimus (1)
Regeneron Pharmaceuticals (2) · Ankyra Therapeutics, Inc (1) · Boundless Bio, Inc. (1) · Centre Leon Berard (1) · Dana-Farber Cancer Institute (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Fudan University (1) · Germans Trias i Pujol Hospital (1) · Instituto de Investigación Biomédica de Salamanca (1) · Jules Bordet Institute (1) · KaliVir Immunotherapeutics (1) · Kupando GmbH (1) · Marissa Lobl (1) · Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji (1) · The Netherlands Cancer Institute (1)
United States (9) · France (2) · Germany (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · China (1) · Italy (1) · Netherlands (1) · Poland (1)
Ann Silk, MD (1) · George Ansstas, MD (1) · Glenn Geidel, MD, MSc (1) · Jason W Chan, MD (1) · Joe Elassal, MD, MBA (1) · Karam Khaddour, MD (1) · Lotje Zuur, Prof. Dr. (1) · Naoka Murakami, MD, PhD (1) · Robert Doebele, MD, PhD (1) · Vincent Ma, MD (1)
2025 (1), KL2TR002374-07 (1)